ATX-304 (formerly O304) vs slu-pp-332

ATX-304 (formerly O304) (B-tier) vs slu-pp-332 (C-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

ATX-304 (formerly O304) — tier B

an investigational oral AMPK activator with one small randomized diabetes trial, a newer obesity pilot, and an animal pharmacokinetic curve that cannot establish a human dosing interval.

the AMPK pharmacology and early human signal are real, but the clinical file is too small and short to support the certainty implied by the current research-chemical market.

65 participants in the published 28-day randomized trial · half-life human terminal half-life not published; approximately 11 hours shown only as a low-confidence mouse apparent-decline proxy · weight loss

slu-pp-332 — tier C

small-molecule pan-ERR agonist marketed as 'exercise in a pill'. real, reproducible mouse data on endurance and fat oxidation. zero human trials, and the molecule itself is not even orally bioavailable.

a small molecule, not a peptide. a synthetic pan-ERR agonist that switches on the same oxidative-metabolism gene program as endurance exercise in mice. preclinical only, no human data, poor oral bioavailability.

ERR pan-agonist · preclinical · half-life not formally reported in the primary literature; circulating vendor half-life figures have no peer-reviewed basis · weight loss

at a glance

• ATX-304 (formerly O304): tier B · 65 participants in the published 28-day randomized trial
• slu-pp-332: tier C · ERR pan-agonist · preclinical

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.